Publication: Cationic CaMKII Inhibiting Nanoparticles Prevent Allergic Asthma
Issued Date
2017-06-05
Resource Type
ISSN
15438392
15438384
15438384
Other identifier(s)
2-s2.0-85020205009
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Molecular Pharmaceutics. Vol.14, No.6 (2017), 2166-2175
Suggested Citation
Angie S. Morris, Sara C. Sebag, John D. Paschke, Amaraporn Wongrakpanich, Kareem Ebeid, Mark E. Anderson, Isabella M. Grumbach, Aliasger K. Salem Cationic CaMKII Inhibiting Nanoparticles Prevent Allergic Asthma. Molecular Pharmaceutics. Vol.14, No.6 (2017), 2166-2175. doi:10.1021/acs.molpharmaceut.7b00114 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/41841
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Cationic CaMKII Inhibiting Nanoparticles Prevent Allergic Asthma
Abstract
© 2017 American Chemical Society. Asthma is a common lung disease affecting over 300 million people worldwide and is associated with increased reactive oxygen species, eosinophilic airway inflammation, bronchoconstriction, and mucus production. Targeting of novel therapeutic agents to the lungs of patients with asthma may improve efficacy of treatments and minimize side effects. We previously demonstrated that Ca2+/calmodulin-dependent protein kinase (CaMKII) is expressed and activated in the bronchial epithelium of asthmatic patients. CaMKII inhibition in murine models of allergic asthma reduces key disease phenotypes, providing the rationale for targeted CaMKII inhibition as a potential therapeutic approach for asthma. Herein we developed a novel cationic nanoparticle (NP)-based system for delivery of the potent and specific CaMKII inhibitor peptide, CaMKIIN, to airways.1 CaMKIIN-loaded NPs abrogated the severity of allergic asthma in a murine model. These findings provide the basis for development of innovative, site-specific drug delivery therapies, particularly for treatment of pulmonary diseases such as asthma.